Overview
United Therapeutics Corporation, based in the United States, operates primarily in the biotechnology sector, focusing on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company has carved a niche in the market through its specialized work on pulmonary arterial hypertension (PAH) and other cardiovascular disorders, with key products like Remodulin, Tyvaso, and Orenitram leading its revenue streams. United Therapeutics is also invested in advanced projects such as the development of organ transplantation solutions including the use of xenotransplantation and ex-vivo lung perfusion to increase organ availability, underscoring its commitment to extending the lives and enhancing the quality of life for its patient community.
Basic Stats
The share price of United Therapeutics Corporation as of September 5, 2025 is $400.52 / share. This is an increase of 31.42% from the prior week. The market cap (or net worth) of United Therapeutics Corporation as of September 5, 2025 is $18,109.62 MM.
The Factor Analysis chart (below right) shows a view of United Therapeutics Corporation from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 18,109.62 MM |
| EV | 16,716.52 MM |
| Shares Out. | 45.22 MM |
| Earnings Date | |
| EPS (TTM) | 27.47 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.33 |
| Short Shares Avail. | 1.30 MM |
| Short Interest | 2.86 MM |
| Short Float | 6.80 % |
| Days to Cover | 1.96 days |
| Risk Free Rate | 4.22 % |
| Price Change (1 yr) | 14.43 % |
| Volatility (1 yr) | 0.48 |
| Beta | 0.48 |
| Sharpe Ratio (1 yr) | 0.21 |
| Sortino Ratio (1 yr) | 0.41 |
| PE Ratio | 14.58 |
| Price/Book | 2.52 |
| Price/TBV | 2.56 |
| Book/Market | 0.40 |
| EBIT/EV | 0.10 |
| EBIT(3yr avg)/EV | 0.08 |
| ROA | 0.18 |
| ROE | 0.22 |
| ROIC | 0.17 |
| CROIC | 0.03 |
| OCROIC | 0.19 |
| Implied Volatility | 32.02 % |
| Put/Call OI Ratio | 1.33 |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for United Therapeutics Corporation is $386.53. The forecasts range from a low of $297.95 to a high of $535.50. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for United Therapeutics Corporation. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-01-11 | Argus Research | Buy | Maintains | |
| 2022-12-06 | UBS | Buy | Initiate | |
| 2022-12-06 | Morgan Stanley | Overweight | Maintains | |
| 2022-12-05 | Goldman Sachs | Sell | Initiate | |
| 2022-11-03 | Oppenheimer | Outperform | Maintains | |
| 2022-11-03 | Morgan Stanley | Overweight | Maintains | |
| 2022-11-03 | JP Morgan | Overweight | Maintains | |
| 2022-11-03 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-10-11 | Morgan Stanley | Overweight | Initiate | |
| 2022-05-24 | Wedbush | Outperform | Maintains | |
| 2022-05-24 | JP Morgan | Overweight | Maintains | |
| 2022-05-24 | Jefferies | Buy | Maintains | |
| 2022-05-24 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-05-24 | Credit Suisse | Outperform | Maintains | |
| 2022-04-19 | JP Morgan | Overweight | Maintains | |
| 2022-02-28 | Wedbush | Outperform | Maintains | |
| 2022-02-25 | Ladenburg Thalmann | Buy | Maintains | |
| 2022-02-11 | BTIG | Neutral | Initiate | |
| 2021-07-14 | Argus Research | Hold | Buy | Upgrade |
| 2021-05-06 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-04-08 | JP Morgan | Overweight | Maintains | |
| 2021-02-22 | Credit Suisse | Outperform | Maintains | |
| 2021-02-16 | Oppenheimer | Outperform | Maintains | |
| 2021-02-01 | HC Wainwright & Co. | Neutral | Buy | Upgrade |
| 2020-07-30 | Wedbush | Outperform | Maintains | |
| 2020-07-30 | Oppenheimer | Outperform | Maintains | |
| 2020-06-25 | HC Wainwright & Co. | Neutral | Maintains | |
| 2020-06-25 | Credit Suisse | Outperform | Maintains | |
| 2020-03-10 | Jefferies | Hold | Buy | Upgrade |
| 2020-02-27 | Cowen & Co. | Market Perform | Outperform | Upgrade |
| 2020-02-13 | Credit Suisse | Outperform | Maintains | |
| 2020-01-31 | JP Morgan | Neutral | Overweight | Upgrade |
| 2019-08-01 | Ladenburg Thalmann | Neutral | Buy | Upgrade |
| 2019-08-01 | Jefferies | Underperform | Hold | Upgrade |
| 2019-07-01 | Credit Suisse | Neutral | Outperform | Upgrade |
| 2019-05-17 | UBS | Sell | Neutral | Upgrade |
| 2019-05-09 | Credit Suisse | Underperform | Neutral | Upgrade |
| 2019-05-02 | Wedbush | Outperform | Outperform | Maintains |
| 2019-03-01 | Barclays | Underweight | Underweight | Maintains |
| 2018-11-19 | Credit Suisse | Underperform | Underperform | Maintains |
| 2018-11-02 | JP Morgan | Neutral | Neutral | Maintains |
| 2018-11-01 | Credit Suisse | Underperform | Underperform | Maintains |
| 2018-10-12 | Standpoint Research | Hold | Buy | Upgrade |
| 2018-08-02 | Wedbush | Outperform | Outperform | Maintains |
| 2018-07-10 | Credit Suisse | Neutral | Neutral | Maintains |
| 2018-05-03 | Credit Suisse | Neutral | Neutral | Maintains |
| 2018-05-03 | Barclays | Underweight | Underweight | Maintains |
| 2018-04-03 | Credit Suisse | Underperform | Neutral | Upgrade |
| 2018-02-22 | Credit Suisse | Underperform | Underperform | Maintains |
| 2018-02-22 | Barclays | Underweight | Underweight | Maintains |
| 2017-04-03 | Cowen & Co. | Outperform | Market Perform | Downgrade |
| 2017-03-30 | UBS | Sell | Initiate | |
| 2017-03-16 | Credit Suisse | Underperform | Initiate | |
| 2017-03-06 | Jefferies | Hold | Underperform | Downgrade |
| 2017-01-19 | Standpoint Research | Buy | Hold | Downgrade |
| 2016-12-14 | Oppenheimer | Outperform | Initiate | |
| 2016-11-29 | Barclays | Equal-Weight | Underweight | Downgrade |
| 2016-10-28 | Ladenburg Thalmann | Neutral | Buy | Upgrade |
| 2016-07-29 | JP Morgan | Neutral | Maintains | |
| 2016-06-15 | H.C. Wainwright | Buy | Neutral | Downgrade |
| 2016-05-24 | Argus | Buy | Hold | Downgrade |
| 2016-04-29 | Ladenburg Thalmann | Buy | Neutral | Downgrade |
| 2016-02-26 | Barclays | Equal-Weight | Maintains | |
| 2016-02-10 | Standpoint Research | Hold | Buy | Upgrade |
| 2015-08-19 | Wedbush | Outperform | Maintains | |
| 2015-04-29 | Leerink Swann | Market Perform | Maintains | |
| 2015-04-29 | JP Morgan | Neutral | Maintains | |
| 2015-04-29 | Jefferies | Hold | Maintains | |
| 2015-04-01 | JP Morgan | Neutral | Maintains | |
| 2015-03-12 | Argus | Hold | Buy | Upgrade |
| 2015-02-25 | JP Morgan | Neutral | Maintains | |
| 2015-02-25 | Jefferies | Hold | Maintains | |
| 2015-01-06 | BTIG Research | Neutral | Initiate | |
| 2015-01-06 | Barclays | Equal-weight | Initiate | |
| 2014-12-16 | JP Morgan | Neutral | Maintains | |
| 2014-12-11 | Credit Suisse | Neutral | Underperform | Downgrade |
| 2014-11-03 | Argus | Buy | Hold | Downgrade |
| 2014-10-15 | Standpoint | Hold | Buy | Upgrade |
| 2014-09-22 | Standpoint Research | Buy | Hold | Downgrade |
| 2014-08-29 | Wedbush | Outperform | Maintains | |
| 2014-07-30 | Credit Suisse | Neutral | Maintains | |
| 2014-06-16 | Credit Suisse | Market Perform | Outperform | Upgrade |
| 2014-04-07 | Standpoint Research | Hold | Buy | Upgrade |
| 2014-01-05 | Goldman Sachs | Sell | Maintains | |
| 2013-12-23 | Ladenburg Thalmann | Neutral | Buy | Upgrade |
| 2013-12-23 | JP Morgan | Underweight | Neutral | Upgrade |
| 2013-07-30 | Standpoint Research | Buy | Hold | Downgrade |
| 2013-07-26 | BMO Capital | Market Perform | Maintains | |
| 2013-05-15 | Standpoint Research | Buy | Hold | Downgrade |
| 2013-02-27 | Deutsche Bank | Hold | Maintains | |
| 2013-02-26 | Jefferies | Hold | Maintains | |
| 2013-02-26 | Brean Capital | Buy | Hold | Downgrade |
| 2013-02-04 | Standpoint | Hold | Buy | Upgrade |
| 2013-01-23 | Guggenheim | Neutral | Initiate | |
| 2012-12-13 | Goldman Sachs | Neutral | Sell | Downgrade |
| 2012-10-24 | JP Morgan | Neutral | Underweight | Downgrade |
| 2012-10-24 | BMO Capital | Outperform | Market Perform | Downgrade |
| 2012-07-26 | Deutsche Bank | Hold | Maintains | |
| 2012-04-30 | Ladenburg Thalmann | Buy | Maintains | |
| 2012-04-27 | Canaccord Genuity | Hold | Downgrade | |
| 2012-03-26 | Canaccord Genuity | Buy | Initiate | |
| 2012-02-14 | Brean Capital | Buy | Maintains | |
| 2023-02-23 | JP Morgan | Overweight | Maintains | |
| 2023-02-23 | Morgan Stanley | Overweight | Maintains | |
| 2023-02-23 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-04-10 | UBS | Buy | Maintains | |
| 2023-04-10 | Morgan Stanley | Overweight | Maintains | |
| 2023-04-21 | Argus Research | Buy | Maintains | |
| 2023-05-04 | Ladenburg Thalmann | Buy | Maintains | |
| 2023-08-03 | Ladenburg Thalmann | Buy | Buy | Maintains |
| 2023-08-03 | Wedbush | Outperform | Outperform | Maintains |
| 2023-08-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-08-03 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-11-02 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-11-02 | Wedbush | Outperform | Outperform | Maintains |
| 2023-11-02 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-02-12 | Goldman Sachs | Sell | Neutral | Upgrade |
| 2024-05-21 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-02-22 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-02-22 | Wedbush | Outperform | Outperform | Reiterate |
| 2024-02-05 | Leerink Partners | Outperform | Initiate | |
| 2024-05-03 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2024-05-02 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-03-07 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-05-02 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-06-12 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-07-11 | TD Cowen | Buy | Buy | Maintains |
| 2024-07-11 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2024-07-08 | UBS | Buy | Buy | Maintains |
| 2024-08-01 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-28 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-11-01 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2024-10-31 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-10-31 | Ladenburg Thalmann | Buy | Buy | Maintains |
| 2024-07-25 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-02-27 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-10-21 | TD Cowen | Buy | Buy | Maintains |
| 2024-08-01 | B of A Securities | Underperform | Underperform | Maintains |
| 2024-10-31 | Argus Research | Buy | Buy | Maintains |
| 2024-10-31 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-09-23 | Jefferies | Buy | Buy | Maintains |
| 2025-04-25 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| 2024-08-20 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-01-08 | UBS | Buy | Buy | Maintains |
| 2025-06-02 | Cantor Fitzgerald | Overweight | Initiate | |
| 2025-07-10 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-04-21 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-04-21 | B of A Securities | Underperform | Neutral | Upgrade |
| 2025-05-01 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-05-01 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-08-13 | UBS | Buy | Buy | Maintains |
| 2025-09-04 | UBS | Buy | Buy | Maintains |
| 2025-05-05 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-09-05 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-07-31 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-07-31 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2025-06-11 | B of A Securities | Neutral | Neutral | Maintains |
| 2025-07-08 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-06-30 | UBS | Buy | Buy | Maintains |
| 2025-09-02 | B of A Securities | Neutral | Neutral | Maintains |
| 2025-09-02 | Jefferies | Buy | Buy | Maintains |
| 2025-09-03 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
